The best tool you have for demonstrating the value of your therapies is your patients—what they say about the compounded medications you dispense to them. read more →
In a Sep 16 letter to NABP CEO Al Carter, FDA states that DTE products “can put patients at harm” and that “therapies containing DTE are biological products subject to licensure under Section 351(i) of the PHS Act.” read more →
One result of last week’s Compounders on Capitol Hill visits has been the creation of a joint congressional letter to FDA’s Center for Veterinary Medicine raising concerns about the great ambiguity in GFI 256 on animal compounding read more →
Express Scripts (ESI) has slashed pharmacy reimbursements for 2023, making it impossible for many independent community pharmacies to participate in the TRICARE pharmacy network. read more →
One result of last week’s Compounders on Capitol Hill has been the creation of a joint congressional letter to FDA’s Center for Veterinary Medicine raising concerns about the great ambiguity in GFI 256 on animal compounding, read more →
